Transce3nd, LLC Mereo Biopharma Group PLC Transaction History
Transce3nd, LLC
- $295 Billion
- Q4 2024
A detailed history of Transce3nd, LLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Transce3nd, LLC holds 127 shares of MREO stock, worth $372. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127Holding current value
$372% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MREO
# of Institutions
95Shares Held
114MCall Options Held
83.4KPut Options Held
424K-
Janus Henderson Group PLC London, X017.1MShares$50.2 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$44.9 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$28.1 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$25.5 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.64MShares$25.3 Million4.71% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $366M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...